Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).
Chula now has an Excellence Chulalongkorn Comprehensive Cancer Center bringing together medical specialists from various areas of expertise to attend to cancer patients using the latest academic and technological know-how to enhance the quality of life and the possibilities of being cured for patients of all types of cancer.
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue.
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer.
Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society (Chulalongkorn Hospital) has become the world’s first institution to have successfully used immunotherapy to treat a breast cancer patient who is now in complete remission with minimal side effects and uplifted quality of life.
A treatment regimen for patients with advanced melanoma that combines the immunotherapy agents relatlimab (anti-LAG-3) and nivolumab (anti-PD-1) delayed time to cancer progression significantly more than nivolumab alone, according to results of a study to be presented June 6 at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Ludwig Cancer Research is proud to announce that the Lausanne Branch of the Ludwig Institute for Cancer Research has received a Team Science Award from the Society for Immunotherapy of Cancer (SITC).
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
A Ludwig Cancer Research study has uncovered a mechanism by which the tumor’s harsh internal environment sabotages T lymphocytes, leading cellular agents of the anticancer immune response.
Changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models
In cell and mouse models, one microRNA showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.
While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches. In a study to be presented at the American Society of Clinical Oncology (ASCO) 2020 virtual meeting, a Roswell Park Comprehensive Cancer Center team reports that in many cases, these newer treatment approaches may reduce the risk of therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) compared to chemotherapy-based treatment strategies.
Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature Neuroscience, is expected to lead to a clinical trial to test the benefits of the treatment in patients. The findings also hold implications for other cancers that do not respond to immunotherapy.
A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.
An analysis of more than 10,000 gliomas and clinical outcomes reported in Nature by scientists in Boston and Paris found that glioma patients whose tumors were hypermutated actually had no significant benefit when treated with checkpoint blockers.
MD Anderson researchers find that treating T cells with panobinostat and IL-21 re-programs them to a powerful central memory T cell type that persists longer.
Research into engineering artificial organs that mimic the functions of human lymph nodes at The University of Alabama in Huntsville (UAH) has garnered one of its professors a $507,777 National Science Foundation (NSF) Faculty Early Career Development Program (CAREER) Award.
Columbia Engineers have engineered probiotics to safely deliver immunotherapies within tumors, including nanobodies against two proven therapeutic targets—PD-L1 and CTLA-4. Continuously released by bacteria, the drugs continue to attack the tumor after just one dose, facilitating an immune response resulting in tumor regression. The versatile probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling the release of effective therapeutic combinations within the tumor for more difficult-to-treat cancers like colorectal cancer.
Ludwig Cancer Research congratulates Ping-Chih Ho on his appointment as Associate Member at the Lausanne Branch of the Ludwig Institute for Cancer Research.
Below are summaries of recent Fred Hutch research findings with links for additional background and media contacts.
The 61st American Society of Hematology Annual Meeting and Exposition will take place Dec. 7–10 in Orlando, Florida
MD Anderson and Takeda today announced an exclusive license agreement and research agreement to develop CAR NK-cell therapies for the the treatment of B-cell malignancies.
Below are summaries of recent Fred Hutch research findings, with links for additional background and media contacts.
Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study